Disease Modifying Anti-Rheumatic Drug Therapy Report

This report is a public document prepared by Komodo Health on behalf of the Centers for Medicare & Medicaid Services Qualified Entity program. It focuses on the utilization patterns of Disease Modifying Anti-Rheumatic Drugs (DMARDs) for patients with rheumatoid arthritis in the United States. The report aims to measure and quantify the extent to which patients receive recommended pharmacological therapies and are monitored for potential side effects. It employs a standard measure endorsed by the National Quality Forum to assess DMARD therapy effectiveness, specifically analyzing data from 2017. The findings indicate significant variations in DMARD usage across different patient demographics, including potential disparities in access to treatment based on race and ethnicity. The report emphasizes the importance of continuous monitoring to identify and address modifiable factors affecting access to evidence-based care. It also outlines the methodology used for measurement, including data sources and calculation processes for DMARD dispense rates.